.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The EMPOwER phase 3 trial evaluated erenumab in adults with episodic migraine from Asia, the Middle East and Latin America—populations under-represented in many earlier migraine studies. Nine hundred participants were randomised to placebo or monthly erenumab 70 mg or 140 mg for three months. Both doses significantly reduced monthly migraine days and acute medication-use days compared with placebo, with consistent benefits across several secondary outcomes. Safety findings were comparable with placebo and no new signals emerged. The study is clinically valuable because treatment effects were demonstrated across a geographically diverse population more representative of real-world global migraine care. For HCPs, the results support considering CGRP receptor blockade irrespective of ethnicity or geography while still tailoring treatment to individual characteristics. The findings also reinforce the role of patient-reported outcomes such as disability and treatment satisfaction alongside headache-day counts. This is a useful evidence base for IANCON's discussion of contemporary migraine management and the expansion of targeted preventive therapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The EMPOwER phase 3 trial evaluated erenumab in adults with episodic migraine from Asia, the Middle East and Latin America—populations under-represented in many earlier migraine studies. Nine hundred participants were randomised to placebo or monthly erenumab 70 mg or 140 mg for three months. Both doses significantly reduced monthly migraine days and acute medication-use days compared with placebo, with consistent benefits across several secondary outcomes. Safety findings were comparable with placebo and no new signals emerged. The study is clinically valuable because treatment effects were demonstrated across a geographically diverse population more representative of real-world global migraine care. For HCPs, the results support considering CGRP receptor blockade irrespective of ethnicity or geography while still tailoring treatment to individual characteristics. The findings also reinforce the role of patient-reported outcomes such as disability and treatment satisfaction alongside headache-day counts. This is a useful evidence base for IANCON's discussion of contemporary migraine management and the expansion of targeted preventive therapy.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
